Literature DB >> 14991049

Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.

Vicente E Torres1, Xiaofang Wang, Qi Qian, Stefan Somlo, Peter C Harris, Vincent H Gattone.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease. The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has been effective in two animal models of PKD with pathologies that are probably related. Here we show, in a mouse model of ADPKD (Pkd2(-/tm1Som)), a similar cellular phenotype and response to OPC31260 treatment, with reduction of renal cyclic AMP (cAMP) levels, prevention of renal enlargement, marked inhibition of cystogenesis and protection of renal function.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14991049     DOI： 10.1038/nm1004

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  170 in total

1.  Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2-Dependent Mechanism in Polycystic Kidney Disease.

Authors:  Nidhi Dwivedi; Shixin Tao; Abeda Jamadar; Sonali Sinha; Christianna Howard; Darren P Wallace; Timothy A Fields; Andrew Leask; James P Calvet; Reena Rao
Journal:  J Am Soc Nephrol       Date:  2020-06-17       Impact factor: 10.121

Review 2.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 3.  Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Hannah A Blair; Gillian M Keating
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

Review 4.  Congenital/inherited kidney diseases: how to identify them early and how to manage them.

Authors:  Jean-Pierre Grünfeld
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

Review 5.  Role of renal TRP channels in physiology and pathology.

Authors:  Viktor Tomilin; Mykola Mamenko; Oleg Zaika; Oleh Pochynyuk
Journal:  Semin Immunopathol       Date:  2015-09-18       Impact factor: 9.623

6.  Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway.

Authors:  Miguel A Garcia-Gonzalez; Luis F Menezes; Klaus B Piontek; Junya Kaimori; David L Huso; Terry Watnick; Luiz F Onuchic; Lisa M Guay-Woodford; Gregory G Germino
Journal:  Hum Mol Genet       Date:  2007-06-16       Impact factor: 6.150

7.  Deficient transient receptor potential vanilloid type 4 function contributes to compromised [Ca2+]i homeostasis in human autosomal-dominant polycystic kidney disease cells.

Authors:  Viktor Tomilin; Gail A Reif; Oleg Zaika; Darren P Wallace; Oleh Pochynyuk
Journal:  FASEB J       Date:  2018-03-19       Impact factor: 5.191

8.  Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.

Authors:  Debbie Zittema; Irina B Versteeg; Ron T Gansevoort; Harry van Goor; Emile de Heer; Kimberley A M Veraar; Dorien J M Peters; Esther Meijer
Journal:  Am J Nephrol       Date:  2016-08-31       Impact factor: 3.754

9.  Structural and functional analyses of liver cysts from the BALB/c-cpk mouse model of polycystic kidney disease.

Authors:  Monalisa N Muchatuta; Vincent H Gattone; Frank A Witzmann; Bonnie L Blazer-Yost
Journal:  Exp Biol Med (Maywood)       Date:  2008-11-07

10.  Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease.

Authors:  Baoxue Yang; Nitin D Sonawane; Dan Zhao; Stefan Somlo; A S Verkman
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.